Barrett's esophagus: Disregulation of cell cycling and intercellular adhesion in the metaplasia-dysplasia-carcinoma sequence

Digestion

Volumn 61, Issue 1, 2000, Pages 1-5

  Tselepis, C ^a   Perry, I ^a   Jankowski, J ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Adhesion; Barrett's metaplasia; Cadherin; Catenin; Cell cycling

Indexed keywords

BILE ACID; CADHERIN; CATENIN; CELL ADHESION MOLECULE; CYCLIN D1; PROTEIN P16; PROTEIN P53;

BARRETT ESOPHAGUS; CELL ADHESION; CELL CYCLE; CELL DAMAGE; COLON POLYPOSIS; COLUMNAR EPITHELIUM; DIGESTIVE SYSTEM INFLAMMATION; DISEASE COURSE; EPITHELIUM DYSPLASIA; ESOPHAGUS CARCINOMA; GENE MUTATION; HUMAN; METAPLASIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REFLUX ESOPHAGITIS; REVIEW; SQUAMOUS EPITHELIUM;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CELL ADHESION; CELL CYCLE; CELL CYCLE PROTEINS; ESOPHAGEAL NEOPLASMS; HUMANS; METAPLASIA;

EID: 0033970129     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007729     Document Type: Review

References (40)

1. Spechler JJ, Goyal RK: Barrett's esophagus. N Engl J Med 1986;315:362-371.
2. Navaratna RM, Winslet T: Barrett's esophagus. Postgrad Med J 1998;74:653-657.
3. Spechler SJ, Robbins AH, Rubins HB, Vincent ME, Heeren T, Doos WG, Colton T, Schimmel EM: Adenocarcinoma and Barrett's esophagus. An overrated risk? Gastroenterology 1998;87: 927-933.
4. Drewitz DJ, Sampliner RE, Garewal HS: The incidence of adenocarcinoma in Barrett's esophagus: A propsective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997; 92:212-215.
5. Prach AT, MacDonald TA, Hopwood DA, Johnston DA: Increasing incidence of Barrett's esophagus: Education, enthusiasm or epidemiology. Lancet 1997;350:933.
6. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF: Rising incidence of adenocarcimona of the esophagus and gastric cardia. JAMA 1991;265: 1287-1289.
7. Spechler SJ: Endoscopic suveillance for patients with Barrett's esophagus: Does the cancer risk justify the practice? Ann Intern Med 1987;106:902-904.
8. Provenzale D, Kemp JA, Arora S, Wong JB: A guide for surveillance of patients with Barrett's esophagus. Am J Gastroenterol 1994;89:670-680.
9. Schnell T, Sontag S, Wanner J, Chintam R, Chejfec G, O'Connel J: Endoscopic screening for Barrett's esophagus, esophageal adneocarcinoma, and other mucosal changes in ambulatory subjects with symptomatic gastroesophageal reflux. Gastroenterology 1985;88:A1567.
10. Mann NS, Tsai MF, Nair PK: Barrett's esophagus in patients with symptomatic reflux oesophagitis. Am J Gastroenterol 1989;84:1494-1496.
11. Johnston MH, Hammond AS, Laskin W, Jones DM: The prevalence and clinical characteristics of short segments of specialized intestinal metaplasia in the distal esophagus on routine endoscopy. Am J Gastreonterol 1996;91:1507-1511.
12. Bremner CG, Lynch VP, Ellis FH: Barrett's esophagus: Congenital or aquired? An experimental study of esophageal mucosal regeneration in the dog. Surgery 1970;68:209-213.
13. Vaezi MF, Richter JE: Double reflux: Double trouble. Gut 1999;44:590-592.
14. Harmon JW, Johnson LF, Maydonovitch CL: Effects of acid and bile salts on the rabbit esophageal mucosa. Dig Dis Sci 1982;26:65-72.
15. Kivilakso E, Fromm D, Silen W: Effect of bile salts and related compounds on isolated esophageal mucosa. Surgery 1980;87:280-285.
16. Nehra D, Howell P, Williams CP, Pye JK, Benyon J: Toxic bile acids in gastro-oesophageal reflux disease: Influence of gastric acidity. Gut 1999;44:598-602.
17. Levi F, Olloyo J, Vecchia CL, Boyle P, Monier P, Savary M: The consumption of tobacco and the risk of adenocarcinoma in Barrett's esophagus. Int J Cancer 1990;45:852-854.
18. Abbas Z, Hussainy A, Ibrahim F, Jafri S, Shaikh H, Khan A: Barrett's esophagus and Helicobacter pylori. J Gastrenterol Hepatol 1995;10:331-333.
19. Ilyas M, Tomlinson IP: Genetic pathways in colorectal cancer. Histopathology 1996;28: 389-399.
20. Jankowski J, Wright N, Meltzer SJ, Triadafilpoulos G, Geboes K, Cassaon AG, Kerr D, Young LS: Molecular evolution of the metaplasia dysplasia adenocarinoma sequence in the esophagus. Am J Pathol 1999;154:965-973.
21. Wu TT, Watanabe T, Heitmiller R, Zahurak M, Forastiere AA, Hamilton SR: Genetic alterations in Barrett esophagus and adenocarcinomas of the esophagus and esophagogastricjunction region. Am J Pathol 1998;153:287-294.
22. Katada N, Hinder RA, Smyrk TC, Hirabayashi N, Perdikis G, Lund RJ, Woodward T, Klingler PJ: Apoptosis is inhibited early in the dysplasia-carcinoma sequence of Barrett esophagus. Arch Surg 1997;132:728-733.
23. Wilson KT, Fu S, Ramanujam KS, Meltzer SJ: Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 1998;58:2929-2934.
24. Soldes OS, Kuick RD, Thompson IA, Hughes SJ, Orringer MB, Iannettoni MD, Hanash SM, Beer DG: Differential expression of Hsp27 in normal esophagus, Barrett's metaplasia and esophageal adenocarcinomas. Br J Cancer 1999;79:595-603.
25. Endo T, Tamaki K, Arimura Y, Itoh F, Hinoda Y, Hareyama M, Irimura T, Fujita M, Imai K: Expression of sulfated carbohydrate chain and core peptides of mucin detected by monoclonal antibodies in Barrett's esophagus and esophageal adenocarcinoma. J Gastroenterol 1998;33: 811-815.
26. Reid BJ, Sanchez CA, Blount PL, Levine DS: Barrett's esophagus: Cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology 1993;105:119-129.
27. Jankowski J, Hopwood D, Wormsley KG: Expression of epidermal growth factor, transforming growth factor alpha and their receptor in gastro-oesophageal diseases. Dig Dis 1993; 11:1-11.
28. Filipe MI, Jankowski J: Growth factors and oncogenes in Barrett's oesophagus and gastric metaplasia. Endoscopy 1993;25:637-641.
29. Brito MJ, Filipe MI, Linehan J, Jankowski J: Association of transforming growth factor alpha (TGFα) and its precursors with malignant change in Barrett's epithelium: Biological and clinical variables. Int J Cancer 1995;60:27-32.
30. Morales CP, Lee EL, Shay JW: In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer 1998;83: 652-659.
31. Mann B, Gelos M, Siedow A, Hanski ML, Gratchev A, Ilyas M, Bodmer WF, Moyer MP, Rieken EO, Buhr HJ, Hanski C: Target genes of β-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci USA 1999;96:1603-1608.
32. Tetsu O, McCormick F: β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398:422-426.
33. Bailey T, Biddlestone L, Shepherd N, Barr H, Warner P, Jankowski J: Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia-adenocarcinoma sequence: Correlation with disease progression and dedifferentiation. Am J Pathol 1998;152:135-144.
34. Washington K, Chiappori A, Hamilton K, Shyr Y, Blanke C, Johnson D, Sawyers J, Beauchamp D: Expression of beta-catenin, alpha-catenin, and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas. Mod Pathol 1998;11:805-813.
35. Behrens J, Birchmeier W: Cell-cell adhesion in invasion and metastasis of carcinomas. Cancer Treat Res 1994;71:251-266.
36. Huber O, Korn R, McLaughlin J, Ohsugi M, Herrmann BG, Kemler R: Nuclear localization of beta-catenin by interaction with transcription factor LEF-1. Mech Dev 1996;59:3-10.
37. Natsugoe S, Mueller J, Kijima F, Aridome K, Shimada M, Shirao K, Kusano C, Baba M, Yoshinaka H, Fukumoto T, Aikou T: Extranodal connective tissue invasion and the expression of desmosomal glycoprotein 1 in squamous cell carcinoma of the esophagus. Br J Cancer 1997;75:892-897.
38. Murray GI, Duncan ME, O'Neil P, McKay JA, Melvin WT, Fothergill JE: Matrix metalloproteinase-1 is associated with poor prognosis in esophageal cancer. J Pathol 1998;185:256-261.
39. Shima I, Sasaguri Y, Kusukawa J, Nakano R, Yamana H, Fujita H, Kakegawa T, Morimatsu M: Production of matrix metalloproteinase 9 (92-kDa gelatinase) by human oesophageal squamous cell carcinoma in response to epidermal growth factor. Br J Cancer 1993;67:721-727.
40. Duncan ME, Richardson JP, Murray GI, Melvin WT, Fothergill JE: Human matrix metallo-proteinase-9: Activation by limited trypsin treatment and generation of monoclonal antibodies specific for the activated form. Eur J Biochem 1998;258:37-43.